Scrip: 世界の医療用医薬品＆製薬産業に関するニュース

Interview: Why Europe's Biotech Prime Time Is Now

By sten-stovall 23 Oct 2019

VC Firm Sofinnova’s Chair Papiernik Speaks After New Fund Launch The chairman of Sofinnova Partners told Scrip his newly launched biotech start-up fund aims to profit from Europe’s top science, relatively realistic asset prices, and geopolitical position between the US and China.

Topic business-strategies drug-review

Scrip: 世界の医療用医薬品＆製薬産業に関するニュース

J&J's Spravato Set For EU Launches Soon

23 Oct 2019

Ketamine-Like Antidepressant Backed By CHMP If the nasal spray is approved by the European Commission, seven months after getting the green light in the US, Spravato will offer the first new mechanism of action in 30 years to treat major depressive disorder.

Topic drug-approval drug-development-landscape

Scrip: 世界の医療用医薬品＆製薬産業に関するニュース

Survival Data Boost Lilly & Novartis's CDK4/6 Assault On Pfizer's Ibrance In Metastatic Breast Cancer

By Alex Shimmings 18 Oct 2019

Pfizer’s dominance of the CDK4/6 inhibitor market will come under renewed pressure as the MONALEESA-3 and MONARCH-2 studies for Novartis’s Kisqali and Lilly’s Verzenio presented at ESMO confirmed their survival benefits in advanced hormone-receptor-positive, HER2-negative breast cancer. The data firmly push the drug class into front-line advanced setting in these patients.

Topic cancer drug-development-landscape research

Scrip: 世界の医療用医薬品＆製薬産業に関するニュース

Ready, Set, Lowest: Who Won China's Latest Drug Bidding War?

18 Oct 2019

Multinationals are feeling the heat to win in China's latest drug procurement battle. The winning prices have surprised even previous winners and may have a profound and long-lasting impact on the pharma sector.

Topic deal-trends strategy

Scrip: 世界の医療用医薬品＆製薬産業に関するニュース

Woodford Debacle Is A Test Of UK Biotech's Resilience

By Andrew McConaghie 18 Oct 2019

Investor's Downfall is Unwelcome Distraction: As once-star investment funds fail, another major investor argues this is opportunity for UK biotech to demonstrate staying power.

Topic BioPharmaceutical Company analysis

Scrip: 世界の医療用医薬品＆製薬産業に関するニュース

Progress Being Made With Cell And Gene Therapy Market Access, But Challenges Remain

18 Oct 2019

Drug developers and payers are coming together long before product approvals to work out payment options for high-cost, high-impact cell and gene therapies, but challenges like portability of commercially insured patients and Medicaid best price requirements remain.

Topic cell-and-gene-therapy drug-development-landscape

Scrip: 世界の医療用医薬品＆製薬産業に関するニュース

Hypoxia Nobel Prize Winners: How Biopharma Is Using Their Research

By Andrew McConaghie 18 Oct 2019

Academic research has once again demonstrated itself to the oxygen of inspiration for industry drug innovation, including a blockbuster-in-waiting.

Topic research biopharmaceutical

Scrip: 世界の医療用医薬品＆製薬産業に関するニュース

Payers Must Brace For Coming Wave Of Cell And Gene Therapies

18 Oct 2019

One regenerative medicine for an ultra-rare disease may have a small impact, but payers will be flooded with dozens of new cell and gene therapies over the next few years. Enzyvant, Novartis and Spark share how they are positioning their complex products.

Topic Cell and gene therapy

Pink Sheet: 世界の薬事規制と承認審査に関するニュース

Pink Sheet Sample Article Pack: The Hottest Topics in Pharma Regulatory Compliance

16 Oct 2019

When you look at newly approved drugs, the latest product reviews and the decisions made during the process, you can gain critical insights to inform your own strategic decisions. That’s what Pink Sheet delivers, and now you can try it for free.

Topic Drug approval Drug development landscape